Strategic positioning for clinical trials in 2021

MyMD will commence a Phase 2 clinical trial of MYMD-1 in COVID19 associated depression in 2021. In addition, we expect to advance MYMD-1 into a phase 2 clinical trial for treatment of diabetes, rheumatoid arthritis, Sarcopenia (aging) and multiple sclerosis. We will also execute studies of Supera-CBD that will enable submission of an Investigational New Drug Application (IND) to the FDA for a Phase 1 clinical trial in epilepsy, addiction, autism and anxiety disorders.

We’re making news in the biotech pharmaceuticals industry

Healthcare Business Today: Three Pillars for the Foundation of a Pharma Merger

Adam Kaplin, M.D., Ph.D., Chief Scientific Officer at MyMD, discusses merger best practices.

MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitors.

Forbes: The Latest Symptom Covid-19 Long Haulers Are Facing: Immune-Mediated Depression

Those infected with COVID-19, especially the “long haulers” - are at increased risk for depression.

All News

  • This field is for validation purposes and should be left unchanged.